natgillin/translations-raw huggingface dataset:
Malaria is spreading to new regions of the world and reappearing in areas where it had been eliminated.
Malaria is spreading to new regions of the world and reappearing in areas where it had been eliminated.
Imported malaria is now a health issue in Europe.
Imported malaria is now a health issue in Europe.
Between 1972 and 2000 the reported number of imported cases increased ten-fold, from 1,500 to over 15,000; more than 700 people in the WHO European Region have died in the last decade.
Between 1972 and 2000 the reported number of imported cases increased ten-fold, from 1,500 to over 15,000; more than 700 people in the WHO European Region have died in the last decade.
Malaria is preventable and curable - with more support for programmes to encourage the use and renewal of mosquito nets, to provide training in recognition of symptoms of malaria, to remove sources of stagnant water, and to equip primary health services with treatment drugs.
Malaria is preventable and curable - with more support for programmes to encourage the use and renewal of mosquito nets, to provide training in recognition of symptoms of malaria, to remove sources of stagnant water, and to equip primary health services with treatment drugs.
In the face of drug resistance and ineffective insecticides, the WHO recommends combining two antimalarials, one being a derivative of artemisinin made from the plant Artemisia annua .
In the face of drug resistance and ineffective insecticides, the WHO recommends combining two antimalarials, one being a derivative of artemisinin made from the plant Artemisia annua .
Cultivation of the plant takes at least 6 months and extraction, processing and manufacturing at least 2 to 5 months.
Cultivation of the plant takes at least 6 months and extraction, processing and manufacturing at least 2 to 5 months.
Therefore, reliable forecasting of global ACT requirements is essential for securing supplies.
Therefore, reliable forecasting of global ACT requirements is essential for securing supplies.
In April 2005, DNDi announced the development of an artesunate and amodiaquine co-formulation in a single tablet, which should become the indispensable treatment for malaria.
In April 2005, DNDi announced the development of an artesunate and amodiaquine co-formulation in a single tablet, which should become the indispensable treatment for malaria.
It will be sold at cost to the countries affected, to international organisations and NGOs.
It will be sold at cost to the countries affected, to international organisations and NGOs.
It will be less expensive than all other combinations containing artemisinin derivatives and is not covered by any patent.
It will be less expensive than all other combinations containing artemisinin derivatives and is not covered by any patent.
This development, funded in part by the EU Research budget, illustrates the potential of R&D into other neglected diseases.
This development, funded in part by the EU Research budget, illustrates the potential of R&D into other neglected diseases.
An estimated 39.4 million people are living with the HIV virus.
An estimated 39.4 million people are living with the HIV virus.
Last year AIDS killed 3.1 million people, the majority in sub-Saharan Africa.
Last year AIDS killed 3.1 million people, the majority in sub-Saharan Africa.
Only 700,000 of the nearly 6 million people in need of antiretroviral (ARV) treatment against HIV in developing countries have access to it, and since July 2004 only 260,000 new patients have benefited from ARV therapy in developing countries.
Only 700,000 of the nearly 6 million people in need of antiretroviral (ARV) treatment against HIV in developing countries have access to it, and since July 2004 only 260,000 new patients have benefited from ARV therapy in developing countries.
ARV prices are high and second-line medicines up to twelve times more expensive than the most affordable WHO-recommended first-line generics.
ARV prices are high and second-line medicines up to twelve times more expensive than the most affordable WHO-recommended first-line generics.
It is estimated that 16 million children under 15 have already lost either one or both parents to HIV/AIDS, leaving the old and young to support each other in families.
It is estimated that 16 million children under 15 have already lost either one or both parents to HIV/AIDS, leaving the old and young to support each other in families.
The needs of children and older people (often carers) should not be neglected.
The needs of children and older people (often carers) should not be neglected.
A massive effort on all fronts of prevention, treatment, care (including palliative care), microbicides and vaccines is needed to achieve a response on a scale that matches that of the global AIDS epidemic.
A massive effort on all fronts of prevention, treatment, care (including palliative care), microbicides and vaccines is needed to achieve a response on a scale that matches that of the global AIDS epidemic.
An estimated 1.8 million people died of TB in 2002.
An estimated 1.8 million people died of TB in 2002.
Southeast Asia accounts for a third of cases globally and Africa accounts for more than a quarter.
Southeast Asia accounts for a third of cases globally and Africa accounts for more than a quarter.
TB accounts for about 13% of AIDS deaths worldwide.
TB accounts for about 13% of AIDS deaths worldwide.
Drug resistant TB is increasing and strains of TB resistant to all major anti-TB drugs have emerged.
Drug resistant TB is increasing and strains of TB resistant to all major anti-TB drugs have emerged.
Particularly dangerous is MultiDrug-Resistant TB.
Particularly dangerous is MultiDrug-Resistant TB.
While drug-resistant TB is generally treatable, it requires up to two years of expensive chemotherapy.
While drug-resistant TB is generally treatable, it requires up to two years of expensive chemotherapy.
The group of diseases caused by Leishmania parasites are transmitted by sandfly bites.
The group of diseases caused by Leishmania parasites are transmitted by sandfly bites.
The leishmaniases are endemic in 88 countries and 12 million people are affected.
The leishmaniases are endemic in 88 countries and 12 million people are affected.
Around 1.5 to 2 million new cases occur annually, and this is rising.
Around 1.5 to 2 million new cases occur annually, and this is rising.
The most life‑threatening form is Visceral Leishmaniasis (VL), commonly known as kala‑azar, which attacks the immune system and from which the 57,000 deaths reported in 1999 is thought to be significantly below the real number.
The most life‑threatening form is Visceral Leishmaniasis (VL), commonly known as kala‑azar, which attacks the immune system and from which the 57,000 deaths reported in 1999 is thought to be significantly below the real number.
Pentavalent antimony, the most widely prescribed drug to treat Leishmaniasis, was discovered a century ago, has serious side effects, requires prolonged treatment and is losing efficacy in some regions due to parasite resistance.
Pentavalent antimony, the most widely prescribed drug to treat Leishmaniasis, was discovered a century ago, has serious side effects, requires prolonged treatment and is losing efficacy in some regions due to parasite resistance.
Although newer treatments exist, they are not optimal due to problems of toxicity, high price or difficulty in administration.
Although newer treatments exist, they are not optimal due to problems of toxicity, high price or difficulty in administration.
Co‑infection with HIV poses an additional challenge.
Co‑infection with HIV poses an additional challenge.
AIDS and VL reinforce one another.
AIDS and VL reinforce one another.
VL accelerates the onset of AIDS and shortens the life expectancy of HIV-infected people, whilst HIV spurs the spread of VL.
VL accelerates the onset of AIDS and shortens the life expectancy of HIV-infected people, whilst HIV spurs the spread of VL.
AIDS increases the risk of VL by 100-1000 times in endemic areas.
AIDS increases the risk of VL by 100-1000 times in endemic areas.
Leishmania/HIV co-infections are considered a real threat, even in south-western Europe.
Leishmania/HIV co-infections are considered a real threat, even in south-western Europe.
Schistosomiasis (bilharzia) infects 200 million people globally of which 20 million are thought to suffer severe consequences causing about 20,000 deaths annually.
Schistosomiasis (bilharzia) infects 200 million people globally of which 20 million are thought to suffer severe consequences causing about 20,000 deaths annually.
Treatment with praziquantel is available but there is concern over the potential for the emergence of resistant parasites.
Treatment with praziquantel is available but there is concern over the potential for the emergence of resistant parasites.
Again there is a need to develop alternative therapies.
Again there is a need to develop alternative therapies.
Sleeping Sickness
Sleeping Sickness
Human African Trypanosomiasis (HAT), or sleeping sickness, is caused by a species of Trypanosoma via the bite of the tsetse fly.
Human African Trypanosomiasis (HAT), or sleeping sickness, is caused by a species of Trypanosoma via the bite of the tsetse fly.
The disease ultimately spreads to the central nervous system when the characteristic signs of sleeping sickness appear.
The disease ultimately spreads to the central nervous system when the characteristic signs of sleeping sickness appear.
HAT is endemic in sub-Saharan Africa with 60 million people at risk.
HAT is endemic in sub-Saharan Africa with 60 million people at risk.
WHO estimates over 300,000 cases of the disease, but most go unreported.
WHO estimates over 300,000 cases of the disease, but most go unreported.
The limited choice of available drugs, their toxicity (causing mortality in 5% of patients), and the disease’s growing unresponsiveness to drugs, make it imperative that new treatments are urgently developed.
The limited choice of available drugs, their toxicity (causing mortality in 5% of patients), and the disease’s growing unresponsiveness to drugs, make it imperative that new treatments are urgently developed.
Chagas Disease
Chagas Disease
American Trypanosomiasis or Chagas Disease is prevalent in Central and South America where 18 million people are infected with the parasite and an estimated 50,000 deaths occur annually.
American Trypanosomiasis or Chagas Disease is prevalent in Central and South America where 18 million people are infected with the parasite and an estimated 50,000 deaths occur annually.
This amounts to about 25% of the region’s population at risk, yet only two drugs, nifurtimox and benznidazole - neither ideal - can treat the acute phase; for chronic Chagas Disease there is no treatment at all.
This amounts to about 25% of the region’s population at risk, yet only two drugs, nifurtimox and benznidazole - neither ideal - can treat the acute phase; for chronic Chagas Disease there is no treatment at all.
Dengue is a mosquito-borne infection found in tropical and sub-tropical regions, predominantly in urban and semi-urban areas.
Dengue is a mosquito-borne infection found in tropical and sub-tropical regions, predominantly in urban and semi-urban areas.
The global prevalence of Dengue has grown dramatically in recent decades and it is now endemic in more than 100 countries.
The global prevalence of Dengue has grown dramatically in recent decades and it is now endemic in more than 100 countries.
Some 2,500 million people - two fifths of the world’s population - are now at risk from dengue.
Some 2,500 million people - two fifths of the world’s population - are now at risk from dengue.
WHO currently estimates 50 million cases of infection worldwide every year.
WHO currently estimates 50 million cases of infection worldwide every year.
Between 1995 and 2001 the number of reported cases more than doubled in the Americas.
Between 1995 and 2001 the number of reported cases more than doubled in the Americas.
In recent years, Aedes Albopictus, a secondary Dengue vector in Asia, has spread to parts of Europe, the USA and other countries thought to be a result of the international trade in used tyres.
In recent years, Aedes Albopictus, a secondary Dengue vector in Asia, has spread to parts of Europe, the USA and other countries thought to be a result of the international trade in used tyres.
There is no specific treatment for dengue fever.
There is no specific treatment for dengue fever.
Vaccine development for Dengue and Dengue Haemorrhagic Fever is difficult but progress is being made.
Vaccine development for Dengue and Dengue Haemorrhagic Fever is difficult but progress is being made.
Ebola Haemorrhagic Fever
Ebola Haemorrhagic Fever
Ebola Haemorrhagic Fever has killed over 1,200 since the Ebola virus was discovered.
Ebola Haemorrhagic Fever has killed over 1,200 since the Ebola virus was discovered.
No specific treatment or vaccine is yet available.
No specific treatment or vaccine is yet available.
Several vaccine candidates are being tested but it could be several years before any are available.
Several vaccine candidates are being tested but it could be several years before any are available.
A new drug therapy has shown early promise in laboratory studies and is being evaluated further.
A new drug therapy has shown early promise in laboratory studies and is being evaluated further.
However, this too will take several years.
However, this too will take several years.
Lymphatic Filariasis
Lymphatic Filariasis
Over 120 million people are infected by Lymphatic Filariasis, known as Elephantiasis; over 40 million of them are seriously incapacitated and disfigured by the disease which spreads because of rapid urban growth.
Over 120 million people are infected by Lymphatic Filariasis, known as Elephantiasis; over 40 million of them are seriously incapacitated and disfigured by the disease which spreads because of rapid urban growth.
Lymphatic Filariasis can cause enlargement of limbs, genitalia and breasts and internal damage to the kidneys and lymphatic system.
Lymphatic Filariasis can cause enlargement of limbs, genitalia and breasts and internal damage to the kidneys and lymphatic system.
In endemic communities up to 50% of men and 10% of women can be affected.
In endemic communities up to 50% of men and 10% of women can be affected.
Treatment is by a once-yearly administration of single doses of albendazole plus either diethylcarbamazine or ivermectin carried out for 4-6 years.
Treatment is by a once-yearly administration of single doses of albendazole plus either diethylcarbamazine or ivermectin carried out for 4-6 years.
Buruli Ulcer
Buruli Ulcer
Buruli Ulcer is an emerging health threat; the third most common mycobacterial infection in healthy people after TB and leprosy.
Buruli Ulcer is an emerging health threat; the third most common mycobacterial infection in healthy people after TB and leprosy.
It destroys skin and tissues and causes deformities.
It destroys skin and tissues and causes deformities.
Lesions occur mainly in the limbs.
Lesions occur mainly in the limbs.
At present, the only treatment available is surgery to remove the lesion and a skin graft if necessary.
At present, the only treatment available is surgery to remove the lesion and a skin graft if necessary.
This is both costly and dangerous, with loss of tissues or permanent disability.
This is both costly and dangerous, with loss of tissues or permanent disability.
Neuropsychiatric Disorders
Neuropsychiatric Disorders
Mental illnesses are common to all countries and are rapidly increasing.
Mental illnesses are common to all countries and are rapidly increasing.
They cause considerable economic and social costs.
They cause considerable economic and social costs.
One in four of us develop one or more such disorders at some stage in life and 450 million people world-wide are affected by mental, neurological or behavioural problems.
One in four of us develop one or more such disorders at some stage in life and 450 million people world-wide are affected by mental, neurological or behavioural problems.
Cost-effective treatments exist for most disorders, but mental health legislation, treatment and community care are not given the priority they deserve.
Cost-effective treatments exist for most disorders, but mental health legislation, treatment and community care are not given the priority they deserve.
Some 121 million people currently live with depression.
Some 121 million people currently live with depression.
Each year 5.8% of men and 9.5% of women will experience a depressive episode and 873,000 people commit suicide each year.
Each year 5.8% of men and 9.5% of women will experience a depressive episode and 873,000 people commit suicide each year.
50 million people are affected by Epilepsy; more than 80% of them in the developing world.
50 million people are affected by Epilepsy; more than 80% of them in the developing world.
70% of people with Epilepsy can be seizure-free if treated with antiepileptic drugs.
70% of people with Epilepsy can be seizure-free if treated with antiepileptic drugs.
Although in most countries the cost of treatment can be as low as $5 per patient per year, the vast majority remain untreated.
Although in most countries the cost of treatment can be as low as $5 per patient per year, the vast majority remain untreated.
In Africa, 80% receive no treatment.
In Africa, 80% receive no treatment.
24 million people have Schizophrenia; 37 million people live with dementia, mainly Alzheimer’s.
24 million people have Schizophrenia; 37 million people live with dementia, mainly Alzheimer’s.
With ageing populations, this is projected to rise rapidly in coming years.
With ageing populations, this is projected to rise rapidly in coming years.
Child and adolescent disorders are common.
Child and adolescent disorders are common.
10-20% of children have mental or behavioural problems.
10-20% of children have mental or behavioural problems.
The overall prevalence of learning disability is between 1% and 3%.
The overall prevalence of learning disability is between 1% and 3%.
It is more common in developing countries because of higher incidence of injuries and deprivation of oxygen at birth and early childhood brain infections.
It is more common in developing countries because of higher incidence of injuries and deprivation of oxygen at birth and early childhood brain infections.
Rasked ja tähelepanuta jäetud haigused arengumaades
Major and Neglected Diseases in Developing Countries
Margrete Auken, Alessandro Battilocchio, Margrietus van den Berg, Danutė Budreikaitė, Marie-Arlette Carlotti, Thierry Cornillet, Nirj Deva, Koenraad Dillen, Alexandra Dobolyi, Fernando Fern?ndez Mart?n, Michael Gahler, Hélène Goudin, Jana Hybášková, Filip Andrzej Kaczmarek, Maria Martens, Miguel Angel Martínez Martínez, Luisa Morgantini, Józef Pinior, José Ribeiro e Castro, Toomas Savi, Frithjof Schmidt, Feleknas Uca, Anna Záborská, Jan Zahradil, Mauro Zani
Margrete Auken, Alessandro Battilocchio, Margrietus van den Berg, Danutė Budreikaitė, Marie-Arlette Carlotti, Thierry Cornillet, Nirj Deva, Koenraad Dillen, Alexandra Dobolyi, Fernando Fernández Martín, Michael Gahler, Hélène Goudin, Jana Hybášková, Filip Andrzej Kaczmarek, Maria Martens, Miguel Angel Martínez Martínez, Luisa Morgantini, Józef Pinior, José Ribeiro e Castro, Toomas Savi, Frithjof Schmidt, Feleknas Uca, Anna Záborská, Jan Zahradil, Mauro Zani
Ettepanek võtta vastu Euroopa Parlamendi ja nõukogu määrus Euroopa Sotsiaalfondi kohta
on the proposal for a regulation of the European Parliament and of the Council on the European Social Fund
EXPLANATORY STATEMENT..............................................................................................39
EXPLANATORY STATEMENT..............................................................................................39
EELARVEKOMISJONI ARVAMUS.......................................................................................43
OPINION of the Committee on Budgets .................................................................43
REGIONAALARENGUKOMISJONI ARVAMUS..................................................................48
OPINION of the Committee on Regional Development ..................................48
naiste õiguste ja soolise võrdõiguslikkuse komisjoNI ARVAMUS .........72
OPINION of the Committee on Women's Rights and Gender Equality ...73
– võttes arvesse komisjoni ettepanekut Euroopa Parlamendile ja nõukogule ( KOM(2004)0493 )
– having regard to the Commission proposal to the European Parliament and the Council ( COM(2004)0493 )
– võttes arvesse EÜ asutamislepingu artikli 251 lõiget 2 ja artiklit 148, mille alusel komisjon esitas Euroopa Parlamendile ettepaneku ( C6‑0090/2004 )
– having regard to Article 251(2) and Article 148 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament ( C6‑0090/2004 )
2 ELT C ... / ELTs seni avaldamata.
OJ C ... / Not yet published in OJ. ,
– võttes arvesse tööhõive- ja sotsiaalkomisjoni raportit ja eelarvekomisjoni, regionaalarengukomisjoni ning naiste õiguste ja soolise võrdõiguslikkuse komisjoni arvamusi ( A6‑0216/2005 ),
– having regard to the report of the Committee on Employment and Social Affairs and the opinions of the Committee on Budgets, the Committee on Regional Development and the Committee on Women's Rights and Gender Equality ( A6‑0216/2005 ),
(2) Kehtestada tuleb erisätted nende tegevusliikide kohta, mida ESF võib finantseerida määruses (EÜ) nr […] [millega nähakse ette üldsätted struktuurifondide ja Ühtekuuluvusfondi kohta] kindlaksmääratud eesmärkide raames.
(2) Specific provisions concerning the type of activities which may be financed by the ESF under the objectives defined in Regulation (EC) No […] [laying down general provisions on the Structural Funds and the Cohesion Fund] need to be laid down.
(2) Kehtestada tuleb erisätted nende tegevusliikide kohta, mida ESF võib finantseerida määruses (EÜ) nr […] [millega nähakse ette üldsätted struktuurifondide ja Ühtekuuluvusfondi kohta] kindlaksmääratud eesmärkide raames vastavalt 25. juuni 2002. aasta määruse (EÜ, Euratom) nr 1605/2002, mis käsitleb Euroopa ühenduste üldeelarve suhtes kohaldatavat finantsmäärust, sätetele .
(2) Specific provisions concerning the type of activities which may be financed by the ESF under the objectives defined in Regulation (EC) No […] [laying down general provisions on the Structural Funds and the Cohesion Fund] need to be laid down in accordance with the provisions of Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities
(2 a) On vajalik säilitada fondide üldstruktuur ja tagada assigneerimine erinevatele eesmärkidele vastavalt määrusele (EÜ) nr …/… [millega nähakse ette üldsätted Euroopa Regionaalarengu Fondi, Euroopa Sotsiaalfondi ja Ühtekuuluvusfondi kohta].
(2a) It is necessary to abide by the overall architecture of the Funds and ensure allocation among the various objectives in accordance with Regulation (EC) No .../... [laying down general provisions on the European Regional Development Fund, the European Social Fund and the Cohesion Fund].
(3) ESF peaks toetama liikmesriikide selliseid tegevuspõhimõtteid, mis on heas kooskõlas Euroopa tööhõivestrateegia alusel väljatöötatud juhiste ja soovitustega ning ühenduse sotsiaalse hõlvamise, haridus- ja koolitusalaste eesmärkidega, selleks et tõhusamalt kaasa aidata Lissabonis ja Göteborgis Euroopa Nõukogu poolt kokkulepitud ühenduse eesmärkide elluviimisele.
The ESF should support the policies of Member States which are closely in line with the guidelines and recommendations made under the European Employment Strategy and the agreed objectives of the Community in relation to social inclusion and education and training, to better contribute to the implementation of the objectives and targets agreed at the Lisbon and Goteborg European Councils.